OPEN SESSION

Venue: Stevenson Room, Delta Chelsea Hotel
Date: Saturday, May 2nd, 2009
Time: 8:00 am
Chairs: CDOG: Dr. Derek Jonker & Dr. Sharlene Gill
RDOG: Dr. Nancy Baxter & Dr. Te Vuong

7:15 am  CONTINENTAL BREAKFAST AVAILABLE

8:00 am  WELCOME AND INTRODUCTION / MEMBERSHIP UPDATE  Dr. D. Jonker

8:15 am  BRIEF UPDATE OF ACTIVE TRIALS  Dr. S. Gill

**CRC.2 (N0147):** A Randomized Phase III Trial of Oxaliplatin Plus 5-FU with or without Cetuximab after Curative Resection for Patients with Stage III Colon Cancer

**CRC.3 (E5202):** A Randomized Phase III Study Comparing 5FU Leucovorin and Oxaliplatin versus 5FU Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers

**CRC.4 (ECOG 5204):** Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation.

**CRC.5 (CALGB 80405):** A Phase III Trial of Irinotecan / 5-FU / Leucovorin or Oxaliplatin / 5FU / Leucovorin with Bevacizumab, or Cetuximab, or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum

**CO.20:** A Phase III Randomizes Study of Brivanib Alaninate (BMS-582664) in Combination with Cetuximab (Erbitux®) versus Placebo in Combination with Cetuximab (Erbitux®) in Patients Previously Treated with Combination Chemotherapy for Metastatic Colorectal Carcinoma

**CO.21:** A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients with Early Stage Colon Cancer: A Randomized Controlled Trial (CHALLENGE)
**IND.187:** A Phase I Study Of AZD2281 In Combination With Irinotecan In Patients With Locally Advanced or Metastatic Incurable Colorectal Cancer

8:30 am **INTERGROUP UPDATES**

Colon Cancer  
Dr. D. Jonker/Dr. S. Gill

Rectal Cancer  
Dr. N. Baxter/Dr. T. Vuong

8:50 am **UPDATE OF TRIALS IN DEVELOPMENT**

9:05 am **OTHER**

9:15 am **NEW TRIAL PROPOSALS / CONCEPTS FOR DEVELOPMENT**

9:45 am **CLOSING REMARKS & ADJOURNMENT**  
Dr. D. Jonker